Outcomes of this trial led to the FDA approval of adjuvant osimertinib, and since 2021, the NCCN has recommended up to three years of adjuvant osimertinib, with or without adjuvant chemotherapy, for resected stage IIB-IIIA or high risk stage IB-IIA, EGFR-mutant NSCLC [16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.